Cargando…
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
INTRODUCTION: Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is t...
Autores principales: | Breitenecker, Kristina, Hedrich, Viola, Pupp, Franziska, Chen, Doris, Řezníčková, Eva, Ortmayr, Gregor, Huber, Heidemarie, Weber, Gerhard, Balcar, Lorenz, Pinter, Matthias, Mikulits, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514905/ https://www.ncbi.nlm.nih.gov/pubmed/37746265 http://dx.doi.org/10.3389/fonc.2023.1238883 |
Ejemplares similares
-
PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma
por: Hedrich, Viola, et al.
Publicado: (2023) -
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
por: Hedrich, Viola, et al.
Publicado: (2021) -
The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003) -
The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017) -
Negative regulation of ErbB family receptor tyrosine kinases
por: Sweeney, C, et al.
Publicado: (2004)